375 | Humans |
198 | Pandemics |
192 | Betacoronavirus |
167 | Coronavirus Infections (epidemiology) |
162 | Pneumonia, Viral (epidemiology) |
116 | Coronavirus Infections (transmission) |
111 | Pneumonia, Viral (transmission) |
106 | Coronavirus Infections (diagnosis) |
92 | Pneumonia, Viral (diagnosis) |
84 | Coronavirus Infections (virology) |
81 | Animals |
79 | Pneumonia, Viral (virology) |
76 | Disease Outbreaks |
75 | Coronavirus Infections (prevention & control) |
67 | China |
67 | Betacoronavirus (genetics) |
62 | Pneumonia, Viral (prevention & control) |
62 | Female |
60 | Male |
57 | China (epidemiology) |
56 | Coronavirus Infections (drug therapy) |
52 | Pneumonia, Viral |
52 | Betacoronavirus (isolation & purification) |
50 | Betacoronavirus (pathogenicity) |
47 | SARS Virus |
47 | Pandemics (prevention & control) |
46 | Adult |
45 | Middle Aged |
45 | Coronavirus Infections |
44 | Clinical Laboratory Techniques |
41 | Coronavirus |
40 | Coronavirus Infections (therapy) |
37 | Pneumonia, Viral (therapy) |
34 | Pneumonia, Viral (drug therapy) |
33 | Pneumonia, Viral (complications) |
33 | Aged |
32 | Travel |
32 | Coronavirus Infections (complications) |
31 | Phylogeny |
27 | Public Health |
27 | Child |
26 | Betacoronavirus (immunology) |
25 | Betacoronavirus (physiology) |
24 | Severe Acute Respiratory Syndrome (virology) |
24 | Genome, Viral |
23 | Young Adult |
23 | Severe Acute Respiratory Syndrome (epidemiology) |
22 | Coronavirus Infections (immunology) |
21 | Adolescent |
20 | Antiviral Agents (therapeutic use) |
19 | Pneumonia, Viral (immunology) |
19 | Coronavirus (isolation & purification) |
18 | Risk Factors |
18 | Chiroptera (virology) |
18 | Betacoronavirus (drug effects) |
18 | Aged, 80 and over |
17 | SARS Virus (pathogenicity) |
17 | Retrospective Studies |
17 | Global Health |
17 | Coronavirus Infections (mortality) |
17 | Child, Preschool |
16 | Pneumonia, Viral (mortality) |
16 | Peptidyl-Dipeptidase A (metabolism) |
16 | Contact Tracing |
15 | Spike Glycoprotein, Coronavirus (chemistry) |
15 | Coronavirus (genetics) |
14 | Tomography, X-Ray Computed |
14 | Severe Acute Respiratory Syndrome |
14 | SARS Virus (genetics) |
14 | Quarantine |
14 | Infant |
14 | Disease Outbreaks (prevention & control) |
14 | Antiviral Agents (pharmacology) |
13 | World Health Organization |
13 | Time Factors |
13 | Middle East Respiratory Syndrome Coronavirus |
13 | Fever (etiology) |
13 | Betacoronavirus (chemistry) |
12 | Zoonoses |
12 | Receptors, Virus (metabolism) |
12 | Pneumonia, Viral (physiopathology) |
12 | Coronavirus Infections (physiopathology) |
12 | Betacoronavirus (classification) |
12 | Amino Acid Sequence |
11 | Zoonoses (virology) |
11 | Spike Glycoprotein, Coronavirus (genetics) |
11 | SARS Virus (immunology) |
11 | Population Surveillance |
11 | Pneumonia, Viral (diagnostic imaging) |
11 | Infection Control (methods) |
11 | Epidemics |
11 | Cough (etiology) |
11 | Coronavirus Infections (diagnostic imaging) |
11 | Cell Line |
10 | Virus Internalization |
10 | Spike Glycoprotein, Coronavirus (immunology) |
10 | Severe Acute Respiratory Syndrome (diagnosis) |
10 | Reverse Transcriptase Polymerase Chain Reaction |
10 | Radiography, Thoracic |
10 | Pneumonia, Viral (pathology) |
10 | Models, Molecular |
10 | Infant, Newborn |
10 | Disease Reservoirs (virology) |
10 | Coronavirus Infections (pathology) |
10 | COVID-19 |
9 | Viral Vaccines |
9 | Severe Acute Respiratory Syndrome (transmission) |
9 | Severe Acute Respiratory Syndrome (immunology) |
9 | Real-Time Polymerase Chain Reaction |
9 | Protein Binding |
9 | Pregnancy |
9 | Middle East Respiratory Syndrome Coronavirus (pathogenicity) |
9 | Medicine, Chinese Traditional |
9 | Italy (epidemiology) |
9 | Infection Control |
9 | Clinical Trials as Topic |
9 | Betacoronavirus (metabolism) |
9 | Antibodies, Viral (immunology) |
8 | Zoonoses (epidemiology) |
8 | Spike Glycoprotein, Coronavirus (metabolism) |
8 | Sequence Alignment |
8 | SARS-CoV-2 |
8 | RNA, Viral (genetics) |
8 | Protein Conformation |
8 | Practice Guidelines as Topic |
8 | Patient Isolation |
8 | Mice |
8 | Italy |
8 | Health Personnel |
8 | Feces (virology) |
8 | Civil Defense |
8 | Chlorocebus aethiops |
8 | Chiroptera |
8 | Basic Reproduction Number |
8 | Antiviral Agents (chemistry) |
7 | Severity of Illness Index |
7 | Sensitivity and Specificity |
7 | Protein Structure, Tertiary |
7 | Protein Domains |
7 | Models, Theoretical |
7 | Lung (diagnostic imaging) |
7 | Incidence |
7 | Immunization, Passive |
7 | Communicable Diseases, Emerging (virology) |
7 | Australia (epidemiology) |
7 | Asymptomatic Diseases |
7 | Antibodies, Viral (blood) |
7 | Alanine (analogs & derivatives) |
7 | Age Factors |
6 | Virus Shedding |
6 | Virus Replication |
6 | Viral Vaccines (immunology) |
6 | Viral Proteins (chemistry) |
6 | Viral Load |
6 | Vero Cells |
6 | United States (epidemiology) |
6 | Spike Glycoprotein, Coronavirus |
6 | SARS Virus (physiology) |
6 | SARS Virus (chemistry) |
6 | Middle East Respiratory Syndrome Coronavirus (genetics) |
6 | Health Knowledge, Attitudes, Practice |
6 | Disease Progression |
6 | Coronavirus (classification) |
6 | Computational Biology |
6 | Communicable Diseases, Emerging |
6 | Communicable Diseases, Emerging (epidemiology) |
6 | Adenosine Monophosphate (analogs & derivatives) |
5 | Structure-Activity Relationship |
5 | Severe Acute Respiratory Syndrome (prevention & control) |
5 | Risk Assessment |
5 | Republic of Korea |
5 | RNA, Viral (analysis) |
5 | Protein Multimerization |
5 | Prognosis |
5 | Pneumonia, Viral (metabolism) |
5 | Pneumonia, Viral (genetics) |
5 | Pneumonia, Viral (blood) |
5 | Peptidyl-Dipeptidase A |
5 | Peptidyl-Dipeptidase A (genetics) |
5 | Nasopharynx (virology) |
5 | Mortality |
5 | Middle East Respiratory Syndrome Coronavirus (drug effects) |
5 | Lung (pathology) |
5 | Internationality |
5 | Information Dissemination |
5 | Influenza A Virus, H1N1 Subtype |
5 | Host-Pathogen Interactions |
5 | Hospitalization |
5 | Genome, Viral (genetics) |
5 | Epidemiological Monitoring |
5 | Dyspnea (etiology) |
5 | Drug Discovery |
5 | Drug Design |
5 | Dose-Response Relationship, Drug |
5 | Disease Reservoirs (veterinary) |
5 | Coronavirus Infections (metabolism) |
5 | Coronavirus Infections (genetics) |
5 | Coronavirus Infections (blood) |
5 | Coronavirus (immunology) |
5 | Computer Simulation |
5 | Comorbidity |
5 | Communicable Disease Control (methods) |
5 | Cluster Analysis |
5 | Binding Sites |
4 | Zoonoses (transmission) |
4 | Virus Replication (drug effects) |
4 | Virus Attachment |
4 | Viral Proteins (metabolism) |
4 | Viral Proteins (genetics) |
4 | Viral Envelope Proteins (immunology) |
4 | Vaccination |
4 | United Kingdom (epidemiology) |
4 | Travel-Related Illness |
4 | Severe Acute Respiratory Syndrome (therapy) |
4 | Severe Acute Respiratory Syndrome (pathology) |
4 | Severe Acute Respiratory Syndrome (drug therapy) |
4 | Sequence Analysis, Protein |
4 | Sentinel Surveillance |
4 | SARS Virus (metabolism) |
4 | SARS Virus (drug effects) |
4 | SARS Virus (classification) |
4 | Republic of Korea (epidemiology) |
4 | Receptors, Virus (genetics) |
4 | Receptors, Virus (chemistry) |
4 | RNA, Viral (isolation & purification) |
4 | Polymerase Chain Reaction |
4 | Pneumonia, Viral (veterinary) |
4 | Pharynx (virology) |
4 | Pandemics (statistics & numerical data) |
4 | Neutralization Tests |
4 | Neoplasms |
4 | Molecular Structure |
4 | Molecular Docking Simulation |
4 | Middle East Respiratory Syndrome Coronavirus (physiology) |
4 | Microbial Sensitivity Tests |
4 | Mass Screening |
4 | Influenza, Human (diagnosis) |
4 | Infectious Disease Transmission, Patient-to-Professional (prevention & control) |
4 | Infectious Disease Incubation Period |
4 | Germany |
4 | Fever |
4 | Evolution, Molecular |
4 | Europe (epidemiology) |
4 | Disease Transmission, Infectious |
4 | Disease Transmission, Infectious (prevention & control) |
4 | Disease Reservoirs |
4 | Disease Models, Animal |
4 | Critical Illness |
4 | Coronavirus Infections (veterinary) |
4 | Cohort Studies |
4 | Clinical Laboratory Techniques (methods) |
4 | Biological Evolution |
4 | Betacoronavirus (growth & development) |
4 | Asymptomatic Infections |
4 | Antibodies, Neutralizing (therapeutic use) |
4 | Alanine (pharmacology) |
4 | Air Travel |
3 | coronavirus |
3 | Viral Envelope Proteins (metabolism) |
3 | Viral Envelope Proteins (chemistry) |
3 | United States |
3 | Uncertainty |
3 | Trypsin (metabolism) |
3 | Surveys and Questionnaires |
3 | Sputum (virology) |
3 | Spike Glycoprotein, Coronavirus (ultrastructure) |
3 | Spike Glycoprotein, Coronavirus (antagonists & inhibitors) |
3 | Singapore (epidemiology) |
3 | Severe acute respiratory syndrome |
3 | Risk |
3 | Respiratory Insufficiency (etiology) |
3 | Respiration, Artificial |
3 | Reproducibility of Results |
3 | Real-Time Polymerase Chain Reaction (methods) |
3 | Public Health Surveillance |
3 | Public Health Practice |
3 | Protein Structure, Secondary |
3 | Pneumonia, Viral (psychology) |
3 | Pneumonia, Viral (etiology) |
3 | Pharyngitis (etiology) |
3 | Personal Protective Equipment |
3 | Personal Protective Equipment (supply & distribution) |
3 | Peptidyl-Dipeptidase A (physiology) |
3 | Peptidyl-Dipeptidase A (chemistry) |
3 | Oropharynx (virology) |
3 | Nucleocapsid Proteins (chemistry) |
3 | Mutation |
3 | Mortality (trends) |
3 | Mental Health |
3 | Mass Screening (methods) |
3 | Lung (virology) |
3 | Interleukin-6 (immunology) |
3 | Interleukin-6 (antagonists & inhibitors) |
3 | Intensive Care Units, Neonatal |
3 | Influenza, Human (epidemiology) |
3 | Infectious Disease Transmission, Vertical |
3 | Immunologic Factors (therapeutic use) |
3 | Immunoglobulin M (blood) |
3 | Immunoglobulin G (immunology) |
3 | Immunoglobulin G (blood) |
3 | Immunization |
3 | HEK293 Cells |
3 | Genetic Variation |
3 | Gene Expression Profiling |
3 | France (epidemiology) |
3 | Forecasting |
3 | Epitopes, T-Lymphocyte (immunology) |
3 | Epitopes, B-Lymphocyte (immunology) |
3 | Epitopes (immunology) |
3 | Environmental Microbiology |
3 | Endocytosis |
3 | Emergency Service, Hospital |
3 | Emergencies |
3 | Drugs, Chinese Herbal (therapeutic use) |
3 | Drug Repositioning |
3 | Drug Evaluation, Preclinical |
3 | Dipeptidyl Peptidase 4 (metabolism) |
3 | Diarrhea (virology) |
3 | Diagnosis, Differential |
3 | Cytokines (metabolism) |
3 | Cytokines (immunology) |
3 | Crystallography, X-Ray |
3 | Cryoelectron Microscopy |
3 | Cross Reactions |
3 | Critical Care |
3 | Cough |
3 | Coronavirus Infections (psychology) |
3 | Community-Acquired Infections (transmission) |
3 | Communicable Diseases, Emerging (transmission) |
3 | Cardiovascular Diseases (virology) |
3 | Bronchoalveolar Lavage Fluid (virology) |
3 | Biomedical Research |
3 | Betacoronavirus (ultrastructure) |
3 | Bayes Theorem |
3 | Autopsy |
3 | Antimalarials (therapeutic use) |
3 | Antibodies, Viral (therapeutic use) |
3 | Antibodies, Neutralizing (immunology) |
3 | Antibodies, Monoclonal, Humanized (therapeutic use) |
3 | Antibodies, Monoclonal (therapeutic use) |
3 | Antibodies, Monoclonal (immunology) |
3 | Anti-Inflammatory Agents (therapeutic use) |
3 | Alphacoronavirus (genetics) |
3 | Alanine (therapeutic use) |
3 | Alanine (chemistry) |
3 | Age Distribution |
3 | Adenosine Monophosphate (therapeutic use) |
3 | Adenosine Monophosphate (pharmacology) |
3 | Adaptive Immunity |
2 | outbreak |
2 | Zoonoses (prevention & control) |
2 | Workflow |
2 | Whole Genome Sequencing |
2 | Whole Genome Sequencing (methods) |
2 | Washington (epidemiology) |
2 | Virus Diseases (virology) |
2 | Virus Diseases (transmission) |
2 | Virus Diseases (drug therapy) |
2 | Virus Attachment (drug effects) |
2 | Virulence |
2 | Viral Vaccines (therapeutic use) |
2 | Viral Proteins |
2 | Viral Proteins (antagonists & inhibitors) |
2 | Viral Proteins (analysis) |
2 | Viral Nonstructural Proteins (genetics) |
2 | Viral Envelope Proteins |
2 | Viral Envelope Proteins (genetics) |
2 | Viral Envelope Proteins (analysis) |
2 | Vaccines, Synthetic |
2 | Two-Hybrid System Techniques |
2 | Treatment Outcome |
2 | Transcriptome |
2 | Testis (virology) |
2 | Testis (metabolism) |
2 | Testis (cytology) |
2 | T-Lymphocytes (immunology) |
2 | Surveillance |
2 | Spouses |
2 | Societies, Medical |
2 | Social Conditions |
2 | Singapore |
2 | Sex Factors |
2 | Severe Acute Respiratory Syndrome (history) |
2 | Severe Acute Respiratory Syndrome (etiology) |
2 | Serologic Tests |
2 | Serologic Tests (methods) |
2 | Seroepidemiologic Studies |
2 | Serine Endopeptidases (metabolism) |
2 | Sequence Homology, Amino Acid |
2 | SARS-CoV |
2 | Respiratory Tract Infections (diagnosis) |
2 | Respiratory System (virology) |
2 | Respiratory Protective Devices |
2 | Respiratory Insufficiency |
2 | Respiratory Distress Syndrome, Adult (therapy) |
2 | Respiration, Artificial (methods) |
2 | Recombination, Genetic |
2 | Recombinant Proteins (therapeutic use) |
2 | Receptors, Virus (ultrastructure) |
2 | Randomized Controlled Trials as Topic |
2 | RNA |
2 | RNA Replicase (metabolism) |
2 | RNA Replicase (genetics) |
2 | RNA Replicase (chemistry) |
2 | RNA Replicase (antagonists & inhibitors) |
2 | Public Policy |
2 | Proteome |
2 | Protein Interaction Mapping |
2 | Protein Interaction Domains and Motifs |
2 | Protein Conformation, alpha-Helical |
2 | Protease Inhibitors (therapeutic use) |
2 | Protease Inhibitors (pharmacology) |
2 | Prevalence |
2 | Pregnancy Outcome |
2 | Pregnancy Complications, Infectious (prevention & control) |
2 | Politics |
2 | Point Mutation |
2 | Pneumonia |
2 | Pneumonia, Viral (enzymology) |
2 | Pneumonia, Viral (economics) |
2 | Plasma |
2 | Personnel, Hospital (statistics & numerical data) |
2 | Perinatal Care |
2 | Patient Care Team |
2 | Pandemics (economics) |
2 | Nucleocapsid Proteins (metabolism) |
2 | Nucleocapsid Proteins (genetics) |
2 | Neuraminidase (metabolism) |
2 | Mouth (virology) |
2 | Molecular Targeted Therapy |
2 | Molecular Dynamics Simulation |
2 | Molecular Diagnostic Techniques (methods) |
2 | Models, Animal |
2 | Middle East Respiratory Syndrome Coronavirus (immunology) |
2 | Microscopy, Electron, Transmission |
2 | Microbial Viability |
2 | Metal Nanoparticles (chemistry) |
2 | Membrane Glycoproteins (metabolism) |
2 | Membrane Glycoproteins (immunology) |
2 | Membrane Glycoproteins (chemistry) |
2 | Membrane Fusion |
2 | Medicine, Chinese Traditional (methods) |
2 | Medical Records |
2 | Medical History Taking |
2 | Masks (supply & distribution) |
2 | Lymphopenia |
2 | Lymphopenia (etiology) |
2 | Internet |
2 | Interferon |
2 | Influenza, Human (transmission) |
2 | Infectious Disease Transmission, Patient-to-Professional |
2 | Immunosuppressive Agents (therapeutic use) |
2 | Immunoglobulin A (blood) |
2 | Immunocompromised Host |
2 | Immunity, Innate |
2 | Immune Evasion |
2 | Hypoxia (etiology) |
2 | Hypertension |
2 | Hypertension (complications) |
2 | Human Activities |
2 | Hot Temperature |
2 | Hospitals |
2 | History, 19th Century |
2 | High-Throughput Nucleotide Sequencing (methods) |
2 | Heart Arrest (etiology) |
2 | Health Planning |
2 | Health Facilities |
2 | Health Communication |
2 | HIV (drug effects) |
2 | Guidelines as Topic |
2 | Gold (chemistry) |
2 | Global Health (trends) |
2 | Global Health (statistics & numerical data) |
2 | Genomics |
2 | Genetic Engineering |
2 | France |
2 | Flow Cytometry |
2 | Fever (virology) |
2 | Fatigue (etiology) |
2 | Family Health |
2 | Evidence-Based Medicine |
2 | Evaluation Studies as Topic |
2 | Eutheria (virology) |
2 | European Union |
2 | Europe |
2 | Epitopes, T-Lymphocyte (genetics) |
2 | Epitopes, B-Lymphocyte (genetics) |
2 | Epitope Mapping |
2 | Epidemiology |
2 | Epidemics (prevention & control) |
2 | Enzyme-Linked Immunosorbent Assay |
2 | Early Diagnosis |
2 | Drug Resistance, Viral |
2 | Drug Development |
2 | Disease Susceptibility |
2 | Disease Outbreaks (statistics & numerical data) |
2 | Disease Notification (statistics & numerical data) |
2 | Disaster Planning |
2 | Diarrhea (etiology) |
2 | Dental Care (standards) |